Who
Frank Torti
President and Vant Chair
Company insider
Files Form 4 as: President and Vant Chair, Roivant Sciences; Director, Immunovant; Director, Arbutus Biopharma; Director, Sio Gene Therapies; Director, Myovant Sciences; Director, Urovant Sciences.
In numbers
- Trades disclosed
- 66
- Buys
- 1
- Sells
- 3
- Bought
- $116K
- Sold
- $164.1M
- Companies
- 6
- Companies where not an officer
- 5
- First trade
- 15 Oct 2018
- Last trade
- 30 Sep 2026
- Last filed
- 2 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 2 Oct 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $1.5M40,309 at $36.57 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $1.4M40,310 at $35.39 | filing |
| 30 Jun 2026filed 2 Jul 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $1.4M40,310 at $35.39 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —174,189 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,325 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT Immunovantoption or derivative · Biotechnology | SEC FORM 4 Code A | —88,325 at $0.00 | filing |
| 7 Apr 2026filed 9 Apr 2026 | IMVT ImmunovantBiotechnology | SEC FORM 4 Code A | —174,189 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $4.4M160,035 at $27.70 | filing |
| 31 Mar 2026filed 2 Apr 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code F | $4.4M160,035 at $27.70 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —587,390 at $0.00 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $2.3M587,390 at $3.85 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $16.2M587,390 at $27.51 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $2.3M587,390 at $3.85 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $16.2M587,390 at $27.51 | filing |
| 23 Feb 2026filed 23 Feb 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —587,390 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $3.9M1,012,610 at $3.85 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,012,610 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Sold | $27.5M1,012,610 at $27.15 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ROIV Roivant Sciencesoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,012,610 at $0.00 | filing |
| 20 Feb 2026filed 23 Feb 2026 | ROIV Roivant SciencesBiotechnology | SEC FORM 4 Code M | $3.9M1,012,610 at $3.85 | filing |
News
Roivant Sciences Says Brepocitinib Meets Primary Goal In Uveitis Trials; Shares RiseROIV · rttnews.com · 21 Oct 2026Head to Head Analysis: Roivant Sciences (NASDAQ:ROIV) vs. Pharming Group (NASDAQ:PHAR)ROIV · dailypolitical.com · 14 Oct 2026Analyzing Roivant Sciences (NASDAQ:ROIV) and Krystal Biotech (NASDAQ:KRYS)ROIV · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Frank Torti; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.